fingolimod hydrochloride has been researched along with thromboxane a2 in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alewijnse, AE; Peters, SL; Spijkers, LJ | 1 |
1 other study(ies) available for fingolimod hydrochloride and thromboxane a2
| Article | Year |
|---|---|
FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.
Topics: Animals; Blood Pressure; Carotid Arteries; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Isoenzymes; Male; Muscle, Smooth, Vascular; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sphingosine; Thromboxane A2; Vascular Resistance; Vasoconstrictor Agents | 2012 |